---
title: Think Life, an Online Self-help Intervention for Coping With Suicidal Ideation
nct_id: NCT03209544
overall_status: COMPLETED
phase: NA
sponsor: University Ghent
study_type: INTERVENTIONAL
primary_condition: Suicidal Ideation
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03209544.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03209544"
ct_last_update_post_date: 2017-07-06
last_seen_at: "2026-05-12T07:22:25.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Think Life, an Online Self-help Intervention for Coping With Suicidal Ideation

**Official Title:** A Randomized Controlled Trial on the Effectiveness of an Online Self-help Intervention for Suicidal Ideation

**NCT ID:** [NCT03209544](https://clinicaltrials.gov/study/NCT03209544)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 724
- **Lead Sponsor:** University Ghent
- **Collaborators:** VU University of Amsterdam
- **Conditions:** Suicidal Ideation
- **Start Date:** 2015-04-23
- **Completion Date:** 2016-02-24
- **CT.gov Last Update:** 2017-07-06

## Brief Summary

The objective of the Think Life study is to test the effect of an online, unguided self-help intervention, i.e. Think Life. The primary hypothesis is that Think Life will reduce suicidal ideation. The secondary hypothesis is that Think Life will lead to improvements in depressive symptoms, hopelessness, rumination, and anxiety. Positive changes are expected after completing Think Life and at follow-up, twelve weeks after baseline.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 years or older
* Have internet access and an e-mail account

Exclusion Criteria:

* No suicidal thoughts (i.e. baseline score on Beck Scale for Suicide Ideation = 0)
```

## Arms

- **Intervention group** (EXPERIMENTAL) — The intervention group gains access to Think Life, an online self-help intervention. During 6 weeks they receive a new module on a weekly basis.
- **Control group** (NO_INTERVENTION) — Waitlist control group. They receive access to Think Life after 12 weeks.

## Interventions

- **Online self-help intervention** (BEHAVIORAL) — The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, \& Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).

## Primary Outcomes

- **Beck Scale for Suicide Ideation** _(time frame: Baseline, and 2, 4, 6 (post-test) and 12 weeks (follow-up) after baseline)_ — Changes in severity of suicidal ideation

## Secondary Outcomes

- **Suicidal Ideation Attributes** _(time frame: Baseline, and 2, 4, 6 (post-test) and 12 weeks (follow-up) after baseline)_
- **Beck Depression Inventory - second edition** _(time frame: Baseline, and 2, 4, 6 (post-test) and 12 weeks (follow-up) after baseline)_
- **Beck Hopelessness Scale** _(time frame: Baseline, and 6 (post-test) and 12 weeks (follow-up) after baseline)_
- **Penn State Worry Questionnaire - Past Week** _(time frame: Baseline, and 6 (post-test) and 12 weeks (follow-up) after baseline)_
- **Hospital Anxiety and Depression Scale** _(time frame: Baseline, and 6 (post-test) and 12 weeks (follow-up) after baseline)_

## Recent Field Changes (last 30 days)

- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03209544.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03209544*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*